knowledge -WSS

knowledge

author：Wikipedia 2025-09-06 08:39:39 - browse：8

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： SAMSHA loosens regulations on methadone treatment centers

WSS

What we need to know about Arena Bioworks

SAMSHA loosens regulations on methadone treatment centers

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Life sciences investors close nearly $6 billion in new funds

General Catalyst, Summa Health deal will turn on physician buy

explore

knowledge

knowledge

Walensky prepares to leave CDC — and Congress — behind

After Sarepta trial failure, Duchenne families brace for more debate

At least 13 dead in Texas as scorching temps continue

Humans aren't the only ones with an imagination. Rats have it too

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Jerome Adams on the need for new antivirals for Covid

Do digital therapeutics have a future in medicine?

United colonoscopy coverage change 'may cost lives,' doctors say

Gene therapy’s promise and the high cost of hope

explore

Life sciences investors close nearly $6 billion in new funds

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Gene therapy’s promise and the high cost of hope

Lung cancer screening guidelines updated for cigarette smokers

Life sciences investors close nearly $6 billion in new funds

Do digital therapeutics have a future in medicine?

Wikipedia

hotspot

focus

focus